Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients

A. Veronesi, D. Crivellari, M. D. Magri, G. Cartei, M. Mansutti, S. Foladore, S. Monfardini

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study was to investigate the activity and the toxicity of vinorelbine (VNB) in a population of patients with locally advanced inoperable or metastatic non-small cell lung cancer (NSCLC) including elderly patients unfit for cisplatin-based chemotherapy. VNB was administered at a dose of 25-30 mg/m2, intravenously, weekly until progression. Of the 83 patients who entered the study (median age 63 years, number of patients aged 570 years = 23, median performance status 80, stage IV in 58 patients, previous chemotherapy in 15 patients), 76 were evaluable. One complete remission and 22 partial remissions were noted (30.2% reponse rate). Toxicity was mild. Median survival was 9 months. No effect of age upon outcome was detected. Thus, single agent VNH is a reasonable option for advanced NSCLC, particularly in elderly patients.

Original languageEnglish
Pages (from-to)1809-1811
Number of pages3
JournalEuropean Journal of Cancer
Volume32
Issue number10
DOIs
Publication statusPublished - Sep 1996

Keywords

  • Elderly patients
  • Non-small cell lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients'. Together they form a unique fingerprint.

Cite this